During the past decade, Maryland Center for MS conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 2 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Maryland Center for MS" #1 collaborator was "Bayer" with 2 trials as a collaborator and "National Institute of Neurological Disorders and Stroke (NINDS)" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "Maryland Center for MS" are "Multiple Sclerosis" (6 trials), "Multiple Sclerosis, Relapsing-Remitting" (2 trials) and "Relapsing Remitting Multiple Sclerosis" (1 trials). Many other conditions were trialed in "Maryland Center for MS" in a lesser frequency.

Most popular intervention types in "Maryland Center for MS" are "Drug" (7 trials), "Biological" (2 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Fampridine-SR" (4 trials), "Placebo" (2 trials), "Alemtuzumab 12 mg" (1 trials), "Alemtuzumab 24 mg" (1 trials) and "Daclizumab (Anti-CD25 Humanized Monoclonal Antibody)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Maryland Center for MS" are 9 trials for "All" genders.

Currently, there are NaN active trials in "Maryland Center for MS". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 9 completed trials in Maryland Center for MS, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Maryland Center for MS, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 7 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".